



At IDRI, our mission is to translate science into global health solutions. We develop vaccines, diagnostics, and therapeutic products that address the world's most neglected infectious diseases.

### **Lance Ching, PhD**

Postdoctoral Scientist

Lance Ching is a Postdoctoral Scientist with the Preclinical Biology group at IDRI. His work focuses on evaluating the prophylactic and therapeutic potential of lead *Mycobacterium tuberculosis* (Mtb) and influenza vaccine antigens, adjuvants, and delivery vehicles. A key component of his research involves designing and implementing in vivo studies in small animal models to assess the safety and toxicity of vaccine candidates, to assess the impact on pathogen burden and disease severity, and to identify immune correlates of protection.

Lance received his BSc in Ecology and Evolutionary Biology from Yale University in 2003. In 2005, he joined an HIV laboratory under the direction of Dr. Leonidas Stamatatos, developing and testing strategies for improving the immunogenicity of HIV-1 Envelope-based vaccines. He obtained his PhD in Pathobiology in 2010 from the School of Public Health and Community Medicine at the University of Washington.